Objective: Isolated visceral artery dissections are rare entities with no current consensus guidelines for treatment and follow-up. This study aims to evaluate the presentation, management, outcomes, and follow-up practices for patients with isolated visceral artery dissections and to compare those with and without symptoms.
Isolated dissection of a visceral artery occurs infrequently; however, improvements in imaging technology and increased use have led to increased identification. 1 Isolated visceral artery dissection may be found incidentally among patients without symptoms or may be identified in conjunction with abdominal pain, back pain, nausea, or vomiting. 2 No current consensus guidelines exist, and treatment varies by surgeon preference, anatomic characteristics, and symptomatology, and may include anticoagulation, antiplatelet, and antihypertensive medications, as well as operative intervention. [3] [4] [5] [6] [7] In addition, few studies have compared the natural history, treatment trends, and outcomes among symptomatic and asymptomatic patients. Given the infrequency of this diagnosis, no large multicenter studies have been published. Furthermore, the majority of current literature consists of case reports and descriptive studies from populations outside of North America. Therefore, this study aims to evaluate the clinical presentation, imaging, treatment, and natural history of isolated visceral artery dissection among both symptomatic and asymptomatic patients in the United States. Initially, 210 patients were identified using the International classification of Diseases, Ninth Revision code for other artery dissection (433.29). Chart review was performed including a review of all imaging studies to identify patients with isolated celiac artery dissections and/or isolated superior mesenteric artery (SMA) dissections. Patients with concomitant aortic dissection or dissection in an artery other than the celiac artery or SMA were excluded (n ¼ 185). Patients were then stratified by symptom status.
Variables. Patient demographics and comorbidities were identified. A symptomatic dissection was defined by presence of abdominal pain, back pain, nausea, or vomiting that was not attributable to other causes. All imaging performed and the indications for each initial imaging study were documented. The frequency and modality of follow-up imaging was at the discretion of the treating physician and included computed tomography angiography (CTA), magnetic resonance angiography (MRA), and duplex ultrasound. Initial anatomic characteristics were obtained from the first CTA imaging study performed and included vessel affected, length of dissection, extension into distal branches, and maximal diameter of the dissected vessel. Vessel stenosis was documented if it exceeded 70%. Thrombus, stenosis, and inflammation were also documented by the attending radiologist and/or attending vascular surgeon. Additional measurements for both initial and follow-up imaging, if not formally dictated in the radiology report, were completed by senior general surgery residents who were blinded to the patient symptom status and before other imaging studies. An aneurysm of a visceral artery dissection was defined as 1.5 times normal diameter (larger than 1.2 cm for the celiac artery and larger than 1.1 cm for the SMA); and a diameter of 2.0 cm or greater was considered an indication for operative repair. 8, 9 A change in vessel size on follow-up imaging was defined as a 2.0-mm increase or decrease in diameter on CTA.
Operative intervention was defined as acute (initial hospitalization) or late (after index discharge). Medical management was defined as any new antiplatelet, new anticoagulation, or new or increased antihypertensive medications. Among patients treated with a new medication, the mean duration of anticoagulation and the proportion treated with lifelong antiplatelet agent for were also documented.
Outcomes assessed included 30-day and 1-year mortality, and length of stay. Mortality data was verified from the Social Security Death Index. All subsequent clinic visits, imaging, and readmissions were reviewed for each patient.
Statistical analyses. All statistical analyses were performed using SPSS statistical software (v 20; IBM Corp, Armonk, NY). Binary variables were recorded as a number and percentage. Continuous variables were assessed as mean 6 standard deviation or median with interquartile range as appropriate and analysis was completed using Fisher exact, c 2 , t-test, and Mann-Whitney test.
A P value of <.05 was considered significant. The Beth Israel Deaconess Medical Center Institutional Review Board approved this study, and informed consent was waived because of the retrospective nature of this study.
RESULTS
Baseline characteristics. Twenty-five patients with isolated visceral artery dissections were identified: 15 (60%) symptomatic and 10 (40%) asymptomatic. The majority of all patients were male (symptomatic: n ¼ 12; 80% vs asymptomatic: n ¼ 6; 60%; P ¼ .38). Patients with symptomatic dissections were younger (50 vs 66 years; P < .01); however, other comorbidities did not differ. Importantly, there were no patients with a known connective tissue disorder. One symptomatic patient reported cocaine use immediately prior to the development of abdominal pain. Three patients had a history of a trauma including two patients with a history of blunt trauma (one at the time of presentation and one 4 years post-trauma). One patient had an iatrogenic traumatic dissection, which occurred during chemoembolization for intra-abdominal cancer. Only the acute blunt trauma patient was symptomatic; however, that patient was noted to have concomitant intra-abdominal injuries making it difficult to decipher the true cause of his abdominal pain (Table I ).
Presentation. All symptomatic patients presented with abdominal pain. Other concurrent symptoms included back pain (n ¼ 5; 33%), nausea (n ¼ 2; 13%), and vomiting (n ¼ 1; 7%). Symptomatic patients were more commonly treated as inpatients (n ¼ 14; 93% vs n ¼ 5; 50%; P ¼ .02) and transferred from an outside hospital (n ¼ 9; 60% vs n ¼ 1; 10%; P ¼ .02). Initial imaging modalities did not differ and the majority of dissections were identified on CTA (symptomatic: n ¼ 15; 100% vs asymptomatic: n ¼ 8; 80%). Two asymptomatic patients had incidental findings on other imaging studies, an MRA for disseminated cancer and an angiogram in a patient who had a dissection caused by chemoembolization (Table II) . For all symptomatic patients, imaging was performed to evaluate abdominal pain. Indications for imaging varied among asymptomatic patients and included surveillance for other diseases (n ¼ 5; 50%), work-up of cardiopulmonary conditions (n ¼ 2; 20%), evaluation of a cecal volvulus (n ¼ 1; 10%), diarrhea (n ¼ 1; 10%), and sepsis (n ¼ 1; 10%) (Table III) .
Anatomic characteristics. Single-vessel dissections occurred most frequently (celiac: n ¼ 12; 48%, SMA: n ¼ 9; 35%); however, 16% (n ¼ 4) of patients presented with both vessels affected. All dissections involving both vessels occurred in the symptomatic group. At diagnosis, the maximum vessel diameter (median, symptomatic: 12 mm vs asymptomatic: 12.5 mm) and length of dissection (symptomatic: 19 mm vs asymptomatic: 21 mm) were similar. The extension of dissection flaps into distal branches occurred in 47% (n ¼ 7) of symptomatic patients and 20% (n ¼ 2) of asymptomatic patients. Symptomatic patients trended toward more frequent vessel stenosis (n ¼ 12, 80% vs n ¼ 4, 40%; P ¼ .09), but this did not achieve significance. Finally, documented thrombus (n ¼ 10; 67% vs n ¼ 1; 10%; P ¼ .01) and inflammation (n ¼ 8; 53% vs n ¼ 1; 10%; P ¼ .04) were more commonly seen in symptomatic patients (Table IV) .
Management. Treatment differed significantly between asymptomatic and symptomatic patients. No new medications were initiated among asymptomatic patients; however, two patients were taking aspirin, and two patients were treated with anticoagulation prior to presentation. A new antiplatelet, anticoagulation, or antihypertensive medication was started in 87% (n ¼ 13) of symptomatic patients (P < .01), and no patients were taking an antiplatelet or anticoagulation prior to presentation. Anticoagulation and aspirin were the most common new medications (n ¼ 10; 67% each). Plavix was prescribed in 20% (n ¼ 3) of symptomatic patients, all of whom also received aspirin. New or increased dosages of antihypertensives were started in 27% (n ¼ 4) of symptomatic patients. Only one symptomatic patient was not started on new anticoagulation or antiplatelet medications, with disseminated cancer (n ¼ 1) documented as the indication. The median time of new anticoagulation therapy was 4.7 months; 90% (n ¼ 9) of patients started on aspirin were continued indefinitely (Table V) . Three symptomatic patients underwent open operations, with two of these patients treated at the time of presentation. One of the two patients undergoing an acute operation initially had angiography and thrombolysis for a severe flow-limiting dissection followed by open revascularization, excision of dissection flap with patch angioplasty, and retrograde stent placement, for worsening abdominal pain and concern for mesenteric ischemia. A second patient underwent open intervention, resection of aneurysm with aortosplenic, and common hepatic artery bypass, after angiogram revealed a pseudoaneurysm at the celiac axis. Both patients had complete symptom resolution following intervention with no short-or long-term complications. A final patient underwent open intervention, resection of aneurysm and dissection flap with aortohepatic bypass and reimplantation of the splenic artery in conjunction with neurolysis of the celiac plexus, after 10 months of chronic abdominal pain and hospital readmissions. This patient was noted to have median arcuate ligament syndrome after extensive work-up and had short-term symptom relief following multiple celiac axis blocks, therefore, the decision was made to proceed with operative intervention for her aneurysmal dilation of the documented dissection and median arcuate ligament syndrome concurrently (Table V) . Despite initial resolution of symptoms postoperatively, this patient developed recurrent abdominal pain, which was not attributed to the dissection.
Outcomes. There were no deaths related to visceral dissections in either group. One asymptomatic patient died within 30 days of diagnosis because of cancer. No other deaths occurred within 1 year of diagnosis. There were no differences in hospital length of stay (4 vs 4 days) or readmissions (n ¼ 2; 13% vs n ¼ 0; 0%) between symptomatic and asymptomatic patients, respectively. Both readmissions occurred in the symptomatic group and were for recurrent abdominal pain. One of these patients underwent an angiogram to better image his vasculature; however, no intervention was performed, the patient was started on antiplatelet and anticoagulation medications, and remained asymptomatic in all future follow-up. One patient was readmitted for chronic abdominal pain and underwent eventual open surgical intervention 10 months after diagnosis, as mentioned above. Out of all 25 patients, this was the only individual (n ¼ 1; 4%) with ongoing abdominal pain after hospital discharge, which was attributed to median arcuate ligament syndrome and recurred despite operative repair (Table VI) . Follow-up imaging was performed for 73% (n ¼ 11) of symptomatic patients and 60% (n ¼ 6) of asymptomatic patients (P ¼ .68); however, only 20% of patients in each group were lost to follow-up. Follow-up imaging was not performed in several patients at the discretion of primary care physicians because of disseminated cancers and advanced age. CTA, MRA, and ultrasound were used to monitor dissections. CTA was used at least once for follow-up in 67% (n ¼ 10) of symptomatic patients and 40% (n ¼ 4) of asymptomatic patients. MRA was used at least once for 7% (n ¼ 1) of symptomatic patients and 30% (n ¼ 3) of asymptomatic patients. Ultrasound was used for 67% (n ¼ 10) of symptomatic patients and 30% (n ¼ 3) of asymptomatic patients (Table VII) . Importantly, among patients who had alternating follow-up with CTA and ultrasound, findings did not differ by more than 2.0 mm in vessel diameter for any patients during a 2-year period. The median follow-up time was 1.5 years for symptomatic patients and 3.8 years in asymptomatic patients (P ¼ .02). Among patients with subsequent imaging, there were no differences in vessel diameter changes both in terms of growth (symptomatic: n ¼ 2; 20% vs asymptomatic: n ¼ 2; 33%) or regression (symptomatic: n ¼ 1; 10% vs asymptomatic: n ¼ 0; 0%), and no vessel exceeded 1.6 cm in maximal diameter. A stable vessel diameter was noted in 70% (n ¼ 7) of symptomatic patients and 67% (n ¼ 4) of asymptomatic patients. Among patients with inflammation noted on their initial CT scan, 50% had continued inflammation on their first follow-up imaging (within 1 year), and all patients were without abdominal pain.
DISCUSSION
This study found that patients with symptomatic visceral artery dissections, compared with asymptomatic dissections, had increased inflammation and thrombus noted on diagnostic imaging with a trend toward increased stenosis. However, no differences in length, diameter, or affected vessel were identified. Symptomatic patients were more commonly treated in the inpatient setting, and current practice at our institution is to treat with both with short-term anticoagulation and lifelong aspirin therapy. No differences were seen in outcomes between asymptomatic patients and those initially symptomatic whose symptoms resolved. Finally, vessel growth was noted in both symptomatic and asymptomatic patients; however, no vessel enlarged to the point where intervention would have been considered (2.0 cm), and there were no ruptures or deaths related to visceral dissections.
The anatomic characteristics of visceral dissections have been described previously regarding aneurysmal dilation, length of dissection, and extension into distal branches. 10 Similar to prior work, we found that vessel dilation did occur in patients with visceral dissections, but no vessels reached the 2.0-cm threshold for operative intervention. 2, 11 Our study also found increased inflammation, thrombus, and stenosis among symptomatic patients. The increased inflammation among symptomatic patients has been noted in one previous study, which suggested that acute inflammation was a potential cause of symptoms in patients with visceral dissection. 12 Importantly though, despite these abnormal findings, no patient with inflammation noted on initial CT scan developed recurrent abdominal pain after discharge, underwent operative intervention, or developed worsening stenosis. Finally, only one of the three patients with vessel dilation in follow-up imaging had inflammation on their initial CTA, suggesting that it is not a good indicator for subsequent vessel change.
Several studies have suggested operative intervention for all symptomatic patients, however, numerous case reports have described successful nonoperative management for both symptomatic and asymptomatic patients. mended an endovascular first approach for all patients with persistent pain and concern for bowel ischemia (8.6% of their population). In our practice, concern for bowel ischemia on clinical or radiologic examination is considered an indication for immediate intervention. Pain from the dissection itself can make the clinical evaluation difficult. The presence of bowel ischemia is primarily diagnosed based on the abdominal examination and leukocytosis. Other laboratory markers are routinely checked, such as lactate and amylase, but these are neither sensitive nor specific. When possible, a biphasic, high resolution mesenteric CTA protocol is also used to evaluate vessel patency and also to look for secondary signs of intestinal malperfusion, including bowel-wall thickening, pneumatosis, or lack of mucosal enhancement. This protocol uses an arterial and early venous phase without oral contrast. 13 We also consider a large aneurysm at the dissection site an appropriate indication for operative intervention. However, our study as well as others have shown successful nonoperative management in patients with stenosis but without evidence mesenteric ischemia. 7 Moreover, given the rarity of surgical intervention and lack of long-term follow-up, no determination should be made as to the preferred operative approach (endovascular vs open). Rather, surgeons should use their operative judgment based on patient anatomy and surgeon skill in the determination of optimal approach. Our study was unable to clarify the optimal medical therapy for symptomatic dissections because most patients were treated with a similar modality (shortterm anticoagulation and ongoing antiplatelet). Our study suggests that it may be safe to treat asymptomatic patients with observation alone given no adverse events including death, mesenteric ischemia, or rupture occurred in our cohort. This is further supported by previous work including studies by Gobble who recommended surveillance alone for the management of asymptomatic visceral dissections. 3, 4 For symptomatic visceral dissections, previous studies have recommended differing management algorithms for the optimal treatment of visceral dissections. Early studies encouraged the use of aggressive operative intervention in this population; however, recent work has focused on conservative therapy using anticoagulation, antiplatelet agents, or observation alone. Anticoagulation has been the most widely studied and has been associated with low morbidity and mortality. 2, 14 In one of the larger studies published, Kim et al 2 successfully treated a series of 27 symptomatic patients with anticoagulation and had no mortality, recurrent abdominal pain, or aneurysmal dilation (greater than 2.0 cm) noted on long-term follow-up. Other studies have suggested that even symptomatic patients may be treated with observation alone; however, failure rates (defined by recurrent symptoms or subsequent operative intervention) as high as 44% (range, 5%-44%) have been reported. 3, 15, 16 Yun et al 15 found no difference in progression of dissection or recurrent pain among those patients treated with anticoagulation (n ¼ 5), antiplatelet (n ¼ 4), or observation (n ¼ 19); however, this study was limited by the number of patients treated medically, and one patient did subsequently undergo bowel resection for ischemia. Given that no consensus exists for optimal treatment for symptomatic visceral dissection, our current practice is derived from the treatment of carotid dissections. No randomized trials have yet been completed comparing antiplatelet and anticoagulation for visceral artery dissections; however, studies on carotid artery dissections, including one randomized, have not shown one modality to be superior in the treatment of carotid dissections. [17] [18] [19] It has been suggesting that short-term anticoagulation may be beneficial in preventing recurrent symptoms with carotid dissection, which typically occur in the first 3 to 6 months, followed by antiplatelet therapy if luminal irregularities persist. 20 It is extrapolation of this evidence to the visceral vessels that informs our hospital's current management for symptomatic visceral dissections, which includes a short course of anticoagulation followed by lifelong aspirin therapy. Given the indolent course and lack of any long-term complications in most studies on visceral dissections, it is possible that a less aggressive approach to medical management may produce similar results, however, given the devastating consequences of late bowel ischemia and failure rates of observational therapy alone, we believe some form of antiplatelet therapy for should be considered for all patients with visceral dissections without a contraindication or major concern (advanced age and concern for falls) for antiplatelet therapy. 3, 4 There may also be a role for blood pressure control, as well as statin therapy, to decrease extension of the dissection and improve stability of plaque and thrombus; however, evidence to guide this practice is lacking. As such, the current practice at our institution is to treat all newly diagnosed patients with visceral dissections with aspirin. There were no late complications in this study including death or rupture. These findings are similar to several previous studies. 5 Importantly, our study also had no patients who underwent late bowel resection or repair for aneurysmal dilation. Moreover, all patients had resolution of abdominal pain, with the exception of one patient later diagnosed with median arcuate ligament syndrome, despite the fact that only 50% of patients had resolution of inflammation seen on their initial CTA. These findings suggest that visceral artery dissections have a relatively benign clinical course even if CT findings persist in long-term follow-up, a finding that has also been suggested previously. 2 In addition, our findings, in the context of previous work, suggest that it is reasonable to use a nonoperative approach for both asymptomatic and symptomatic patients who do not have evidence of mesenteric ischemia or associated large aneurysm (>2.0 cm). The concern for aneurysmal degeneration is widely cited as the indication for long-term surveillance in patients with isolated visceral artery dissections, and in fact, vessel diameter enlargement was noted in both asymptomatic and symptomatic patients, despite differing management. Importantly, however, no patients progressed to a diameter requiring intervention. Park et al 4 described their institution's preferred imaging regimen to be a repeat CTA at 1 month, then every 6 months for 2 years, followed by ongoing yearly imaging. Despite the indolent course noted in the current study, we believe that routine surveillance is reasonable and follow-up imaging should not be ceased given that aneurysmal degeneration and rupture have been reported in recent literature. 10 Finally, despite previous studies using CTA for follow-up, we found ultrasound imaging performed equally well. As a result, the current practice at our institution is to survey patients with an initial follow-up CTA and ultrasound at 1 month. If ultrasound and CT imaging are consistent and stable, ultrasound imaging is then completed at 6 months and annually thereafter, with further CTA and MRA imaging reserved for those patients who develop symptoms or concerning ultrasound findings, such as extension of dissection, increase in vessel size, or poor image quality. We believe such an imaging strategy both decreases radiation exposure for patients and costs to the system, while still delivering appropriate quality care. This study has several limitations. First, it is a single center retrospective analysis, with results that may not be generalizable. Because of the rarity of visceral artery dissection, this study is limited by small sample size; however, it remains one of the largest patient cohorts in the literature and is one of the few studies that compare symptomatic and asymptomatic patients. As a result of our small sample size, multivariable analysis was not possible, and as such results could not be adjusted for age. In addition, several patients did not have CTA images available in our electronic record system and as such were able to be evaluated only those data documented in radiology reports. As a result, incomplete anatomic details existed for vessel diameter (n ¼ 4) and length of dissection (n ¼ 3). Finally, follow-up imaging and timing were not uniform. However, despite these limitations, the strengths of this dataset are the detailed anatomic variables and extensive follow-up.
CONCLUSIONS
Among patients with visceral artery dissection, inflammation and thrombosis were more common among symptomatic patients. There was no aneurysmal degeneration necessitating operative intervention or subsequent rupture in follow-up. However, diameter enlargement did occur in both groups despite differing treatment modalities. The risk of aneurysmal growth suggests that routine surveillance is appropriate; however, because no patients developed recurrent symptoms or underwent intervention attributable to complications from dissection, annual follow-up and use of ultrasound imaging seem reasonable to decrease radiation exposure and cost. 
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